These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36509998)

  • 1. Targeting PEA3 transcription factors to mitigate small cell lung cancer progression.
    Shia DW; Choi W; Vijayaraj P; Vuong V; Sandlin JM; Lu MM; Aziz A; Marin C; Aros CJ; Sen C; Durra A; Lund AJ; Purkayastha A; Rickabaugh TM; Graeber TG; Gomperts BN
    Oncogene; 2023 Feb; 42(6):434-448. PubMed ID: 36509998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
    Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
    Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
    Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
    J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two novel determinants of etoposide resistance in small cell lung cancer.
    Lawson MH; Cummings NM; Rassl DM; Russell R; Brenton JD; Rintoul RC; Murphy G
    Cancer Res; 2011 Jul; 71(14):4877-87. PubMed ID: 21642373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
    Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
    J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
    Yang X; Bai F; Xu Y; Chen Y; Chen L
    Cell Physiol Biochem; 2017; 43(3):1126-1139. PubMed ID: 28977798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways.
    Song Y; Sun Y; Lei Y; Yang K; Tang R
    Cancer Med; 2020 Jan; 9(1):259-268. PubMed ID: 31692299
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
    Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
    Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
    Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
    Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
    Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.